Is platinib classified as a banned drug?

According to the current relevant information, pralsetinib (Pralsetinib) is not classified as a banned drug. However, the legal status and regulations of drugs may vary from country to country. Platinib is an oral small molecule tyrosine kinase receptor inhibitor mainly used to treat cancers caused by RET gene mutations or fusions. It is not classified as a banned drug but is approved to treat patients with certain types of cancer.

However, like other drugs, platinib has its limitations and precautions. For example, it is contraindicated in patients who are allergic to platinib or its components, and it is also contraindicated in pregnant women because of possible harm to the fetus. In addition, platinib should be used with caution in children, patients with severe renal impairment, and patients with moderate or severe hepatic impairment. There are also some drug and food interactions you need to be aware of when using platinib. For example, grapefruit and grapefruit juice may interfere with the metabolism of Platinib and increase its concentration in the body, which may result in increased efficacy or worsening of side effects. Therefore, patients should avoid grapefruit and grapefruit juice while taking platinib.

In addition, platinib may interact with certain drugs when used together, resulting in changes in drug efficacy or increased side effects. Therefore, before using platinib, patients should inform their doctor about all medications they are taking, including prescription drugs, over-the-counter drugs, and herbal supplements. In short, platinib is not classified as a banned drug, but a treatment drug for specific types of cancer. When using it, you need to follow your doctor's recommendations and precautions to ensure the safety and effectiveness of the drug.